Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3937-3941

  Al Batran, Salah Eddin ^a   Rafiyan, Mohammad Reza ^a   Atmaca, Akin ^a   Neumann, Antje ^a   Karbach, Julia ^a   Bender, Armin ^a   Weidmann, Eckhart ^a   Altmannsberger, Hans Michael ^a   Knuth, Alexander ^b   Jäger, Elke ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FRESH FROZEN PLASMA; GLYCOPROTEIN GP 100; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

ADVANCED CANCER; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER PATIENT; CANCER SURVIVAL; CELL INFILTRATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; NEOPLASM STAGING;

EID: 20944432811     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4621     Document Type: Article

References (30)

1. Vesalainen S, Lipponen P, Talja M. et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30:1797-803.
2. Halpern AC, Schuchter LM. Prognostic models in melanoma. Semin Oncol 1997;24:2-7.
3. Marrogi AJ, Munshi A, Merogi AJ, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma. Int J Cancer 1997;74:492-501.
4. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
5. Nakano O, Sato M, Naito Y. et al. Proliferate activity of intratumoral CD8(+) T-lymphocyte as a prognostic factor in human renal cell carcinoma: clinicopathoiogic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.
6. + T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-6.
7. Zhang L, Conejo-Garcia JR, Katsaros D. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;16:203-13.
8. Barbatis C, Woods J, Morton JA, et al. Immunohistochemical analysis of HLA (A, B, C) antigens in liver disease using a monoclonal antibody. Gut 1981;22:985-91.
9. Chen YT, Stockert E, Jungbluth A, et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A 1996;93:5915-9.
10. Jungbluth AA, Iversen K, Coplan K, et al. T3I1-an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract 2000;196:235-42.
11. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996;19:192-205.
12. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J Cancer 2001;92:856-60.
13. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, Proc Natl Acad Sci U S A 1997;94;1914-8.
14. Stockert E, Jäger E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
15. Old LJ. Immunotherapy for cancer. Sci Am 1996;275:136-43.
16. Rosenberg SA. A new era of cancer immunotherapy: converting theory to performance. CA Cancer J Clin 1999;49:70-3.
17. Hofbauer GF, Kamarashev J. Geertsen R. et al. Melan, A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res 1998;8:337-43.
18. Hofbauer GF, Kamarashev J, Geertsen R, et al. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol 1998;25:204-9.
19. Munzarova M, Zemanova D, Rejthar A. et al. HLA-DR antigen expression on melanoma metastases and the course of the disease. Cancer Immunol Immunother 1989;30:185-9.
20. Taramelli D, Fossati G, Mazzocchi A, et al. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res 1986;46:433-9.
21. Geertsen RC, Hofbauer GF, Yue F, et al. Higher frequency of selective losses of HLAA and B allospecificities in metastasis than in primary melanoma lesions. J Invest Dermatol 1998;111:497-502.
22. Mendez R, Serrano A, Jager E, et al. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens 2001;57:508-19.
23. Jager E. Ringhoffer M, Altmannsberger M. et al. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma, Int J Cancer 1997;10:142-7.
24. Khong HT, Wang QJ. Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004;27:184-90.
25. Maeurer MJ, Gollin SM, Storkus WJ, et al. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 1996;2:641-52.
26. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003;195:346-55.
27. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004;53:844-54.
28. Atkins D, Ferrone S, Schmahl GE, et al. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 2004;171:885-9.
29. Bernsen MR, Diepstra JH, van Mil P, et al. Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells. J Pathol 2004;202:70-9.
30. Hald J, Rasmussen N, Claesson MH. In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells. Cancer Immunol Immunother 1994;39:383-90.